From: Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union
Type of claim
FDA-granted claim (N = 5 products)
EMA-granted claim (N = 5 products)
Total claims (N = 5 products)
Symptom: pain
2
4
6
Prostate cancer–specific HRQOL
0
Generic HRQOL
1
Total claims
7
9